Core Viewpoint - The stock of Shangrong Medical (002551) has shown a decline in both price and performance metrics, indicating potential challenges in the company's financial health and market position [1][3]. Financial Performance - As of February 11, 2026, Shangrong Medical's stock closed at 3.88 yuan, down 0.77% with a trading volume of 102,400 hands and a transaction value of 39.78 million yuan [1]. - The company reported a net profit of -35.13 million yuan for the first three quarters of 2025, a significant decline of 338.5% year-on-year [3]. - The gross profit margin for Shangrong Medical stands at 14.35%, compared to the industry average of 50.61%, ranking 123 out of 129 in the medical device sector [3]. Market Position - Shangrong Medical's total market capitalization is 3.281 billion yuan, significantly lower than the industry average of 11.062 billion yuan, placing it at 105 out of 129 in the industry ranking [3]. - The company's price-to-earnings ratio (P/E) is -70.05, while the industry average is 86.33, indicating a negative earnings performance relative to peers [3]. Capital Flow - On February 11, 2026, the net inflow of main funds was 1.983 million yuan, accounting for 4.98% of the total transaction value, while retail investors experienced a net outflow of 877,700 yuan, representing 2.21% of the total [1][2]. - Over the past five days, the stock has seen fluctuating capital flows, with notable net outflows from retail investors on multiple days, indicating a lack of confidence among smaller investors [2].

Core Viewpoint - The financial performance of Shangrong Medical (002551) shows significant declines in revenue and net profit for the first three quarters of 2025, indicating potential challenges for the company moving forward [2]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [2]. - The net profit attributable to shareholders was -35.13 million yuan, reflecting a year-on-year decline of 338.5% [2]. - The net profit after deducting non-recurring gains and losses was -42.33 million yuan, down 1336.59% year-on-year [2]. - In Q3 2025 alone, the company recorded a main revenue of 225 million yuan, a decrease of 39.25% compared to the same quarter last year [2]. - The net profit for Q3 was -27.37 million yuan, marking a decline of 4004.28% year-on-year [2]. - The net profit after deducting non-recurring gains and losses for Q3 was -29.81 million yuan, down 2776.04% year-on-year [2]. - The company's debt ratio stands at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [2]. - The gross profit margin is reported at 14.35% [2]. Market Activity - As of February 9, 2026, Shangrong Medical's stock closed at 3.9 yuan, with an increase of 1.04% [1]. - The turnover rate was 1.69%, with a trading volume of 103,500 hands and a transaction amount of 40.33 million yuan [1]. - On February 9, the net outflow of main funds was 4.80 million yuan, accounting for 11.91% of the total transaction amount [1]. - Retail investors saw a net inflow of 4.27 million yuan, representing 10.6% of the total transaction amount [1].

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净齿比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-06 | 3.86 | 0.26% | -71.31万 | -1.80% | -146.15万 | -3.69% | 217.46万 | 5.49% | | 2026-02-05 | 3.85 | -0.52% | -214.98万 | -6.15% | 12.01万 | 0.34% | 202.97万 | 5.80% | | 2026-02-04 | 3.87 | 1.84% | -30.77万 | -0.56% | -373.81万 | -6.80% | 404.58万 | 7.36% | | 2026-02-03 | 3.80 | 0.80% | 144.41万 | 4.30% | -136.37万 | -4.06% | -8.04万 | -0.24% | | 2026-02-02 | 3.77 | -0.53% | -66.20万 | -1.74% | ...

Core Viewpoint - The financial performance of Shangrong Medical (002551) has significantly declined, with a notable drop in revenue and net profit for the first three quarters of 2025 compared to the previous year [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 754 million yuan, a decrease of 24.85% year-on-year [2]. - The net profit attributable to shareholders was -35.13 million yuan, down 338.5% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was -42.33 million yuan, a decline of 1336.59% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 225 million yuan, a decrease of 39.25% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -27.37 million yuan, down 4004.28% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was -29.81 million yuan, a decline of 2776.04% year-on-year [2]. - The company's debt ratio stood at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [2]. - The gross profit margin was 14.35% [2]. Market Activity - As of February 5, 2026, Shangrong Medical's stock closed at 3.85 yuan, down 0.52% [1]. - The turnover rate was 1.48%, with a trading volume of 90,500 hands and a transaction amount of 34.98 million yuan [1]. - On February 5, the net outflow of main funds was 2.15 million yuan, accounting for 6.15% of the total transaction amount [1]. - The net inflow of retail funds was 2.03 million yuan, representing 5.8% of the total transaction amount [1].

Group 1 - The core viewpoint of the news is that Shangrong Medical (002551) has experienced a significant decline in its financial performance for the first three quarters of 2025, with a notable drop in both revenue and net profit [2] - As of February 4, 2026, the stock price of Shangrong Medical closed at 3.87 yuan, reflecting a 1.84% increase, with a trading volume of 143,000 hands and a total transaction amount of 54.99 million yuan [1] - The company's main business includes the production and sales of medical products, medical services, and health industry operations [2] Group 2 - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85%, and a net profit attributable to shareholders of -35.13 million yuan, a decline of 338.5% [2] - In the third quarter of 2025 alone, the company recorded a main revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.37 million yuan, a decrease of 4004.28% [2] - The company's debt ratio stands at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan, while the gross profit margin is reported at 14.35% [2]

Group 1 - The core viewpoint of the news is that Shangrong Medical (002551) has experienced a significant decline in both revenue and net profit for the first three quarters of 2025, indicating financial distress [2] - As of January 28, 2026, Shangrong Medical's stock closed at 3.83 yuan, down 2.3%, with a turnover rate of 3.13% and a trading volume of 191,200 hands, amounting to a total transaction value of 73.6461 million yuan [1] - The company's main business includes the production and sales of medical products, medical services, and health industry operations [2] Group 2 - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85%, and a net profit attributable to shareholders of -35.1253 million yuan, a year-on-year decline of 338.5% [2] - In the third quarter of 2025 alone, the company recorded a main revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.367 million yuan, reflecting a staggering year-on-year decrease of 4004.28% [2] - The company's debt ratio stands at 23.31%, with investment income of 10.2049 million yuan and financial expenses of -3.7891 million yuan, while the gross profit margin is reported at 14.35% [2]

Core Viewpoint - The financial performance of Shangrong Medical (002551) has significantly declined, with a notable drop in revenue and net profit for the first three quarters of 2025 compared to the previous year [2]. Group 1: Financial Performance - For the first three quarters of 2025, the company's main revenue was 754 million yuan, a decrease of 24.85% year-on-year [2]. - The net profit attributable to the parent company was -35.13 million yuan, representing a decline of 338.5% year-on-year [2]. - The net profit after deducting non-recurring items was -42.33 million yuan, down 1336.59% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 225 million yuan, a decrease of 39.25% year-on-year [2]. - The single-quarter net profit attributable to the parent company was -27.37 million yuan, a decline of 4004.28% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -29.81 million yuan, down 2776.04% year-on-year [2]. - The company's debt ratio was 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [2]. - The gross profit margin was 14.35% [2]. Group 2: Market Activity - As of January 27, 2026, the stock closed at 3.92 yuan, down 1.51%, with a turnover rate of 3.51% and a trading volume of 214,600 hands, amounting to a transaction value of 83.43 million yuan [1]. - On January 27, the net outflow of main funds was 9.93 million yuan, accounting for 11.9% of the total transaction value, while retail investors had a net inflow of 10.12 million yuan, representing 12.14% of the total transaction value [1].

截至2026年1月23日收盘，尚荣医疗(002551)报收于3.91元，上涨0.26%，换手率1.47%，成交量9.0万 手，成交额3517.7万元。 当日关注点 交易信息汇总 尚荣医疗发布业绩预告，预计2025年全年每股收益亏损:0.142元至0.2011元。尚荣医疗发布业绩预告， 预计2025年全年归属净利润亏损1.2亿元至1.7亿元。尚荣医疗发布业绩预告，预计2025年全年扣非后净 利润亏损1.36亿元至1.86亿元。 公司公告汇总 深圳市尚荣医疗股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为-17,000.00 万元至-12,000.00万元，扣除非经常性损益后的净利润为-18,619.26万元至-13,619.26万元。业绩亏损主要 原因包括医院工程项目减少、回款不及预期导致坏账准备增加、医疗耗材出口业务受国际形势影响收入 下降且成本上升、汇率波动带来汇兑损失增加以及资产减值准备计提增加。本次业绩预告未经注册会计 师审计，最终数据以2025年年度报告为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建 ...

Group 1 - The company expects a negative net profit for the fiscal year 2025, which spans from January 1, 2025, to December 31, 2025 [2] - The financial data related to this profit forecast has not been audited by a registered accounting firm, but preliminary discussions have taken place, and no significant discrepancies were noted as of the disclosure date [2][3] Group 2 - The main reasons for the expected performance decline include a reduction in hospital engineering projects due to industry conditions, leading to decreased revenue from medical engineering services [3] - There has been an increase in bad debt provisions due to lower-than-expected collections from hospital engineering projects [3] - The export business of medical consumables has been negatively impacted by international circumstances, resulting in decreased revenue and increased costs, which have led to a decline in gross profit margin [3] - Currency fluctuations have caused an increase in exchange losses recognized by the company [3] - The company has increased its provisions for asset impairment during this reporting period [3]

Core Viewpoint - Shenzhen Shangrong Medical Co., Ltd. is expected to report significant losses for the fiscal year 2025, primarily due to various operational challenges and external market conditions [1] Financial Performance - The company's stock closed at 3.91 yuan on January 23, 2026, reflecting a 0.26% increase from the previous trading day, with a total market capitalization of 3.306 billion yuan [1] - The projected net profit attributable to shareholders for 2025 is expected to be between -170 million yuan and -120 million yuan, while the net profit after deducting non-recurring gains and losses is forecasted to be between -186.1926 million yuan and -136.1926 million yuan [1] Reasons for Losses - The anticipated losses are attributed to several factors, including: - A decrease in hospital engineering projects - Lower-than-expected receivables leading to increased bad debt provisions - A decline in revenue from medical consumables exports due to international market conditions, alongside rising costs - Increased foreign exchange losses due to currency fluctuations - Higher asset impairment provisions [1]